









Markets
/
Stocks
/
nasdaq-okyo
/

OKYO Pharma Ltd

OKYO

1.980USD

-0.090-4.35%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

71.32MMarket Cap

--P/E TTM



OKYO Pharma Ltd

1.980

-0.090-4.35%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

118 / 175

Overall Ranking

429 / 4720

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Buy

Current Rating

10.000

Target Price

+383.09%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

OKYO Pharma Limited is a United Kingdom-based clinical stage biopharmaceutical company developing therapies for the treatment of dry eye disease (DED) and neuropathic corneal pain (NCP). The Company is focused on the discovery and development of novel molecules to treat inflammatory DED and ocular pain. Its research program is focused on a novel G Protein-Coupled Receptor (GPCR). The Company is developing OK-101, its lead preclinical product candidate, for the treatment of DED. OK-101 is focused on keratoconjunctivitis sicca, commonly referred to as DED, which is a multifactorial disease caused by an underlying inflammation resulting in the lack of lubrication and moisture in the surface of the eye. The Company also plans to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis. It is also evaluating OK-201, a bovine adrenal medulla (BAM), lipidated-peptide preclinical analogue candidate that is in the developmental stage.

Undervalued

The company’s latest PE is -16.61, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 15.34M shares, increasing 15.91% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 0.00 shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

There is no financial score for this company; the Pharmaceuticals industry's average is 7.84.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is -17.37, which is -79.59% below the recent high of -3.54 and 9.28% above the recent low of -15.76.

Score

Industry at a Glance

Previous score

1.20

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 118/175

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.00, which is higher than the Pharmaceuticals industry's average of 7.78. The average price target for OKYO Pharma Ltd is 10.00, with a high of 13.00 and a low of 7.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 2 analysts

Buy

Current Rating

10.000

Target Price

+383.09%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

179

Total

Median

Average

Company name

Ratings

Analysts

OKYO Pharma Ltd

OKYO

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Eli Lilly and Co

LLY

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 6.24, which is lower than the Pharmaceuticals industry's average of 6.84. Sideways: Currently, the stock price is trading between the resistance level at 2.43 and the support level at 1.89, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.24

Change

0.19

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(5)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.014

Sell

RSI(14)

29.796

Sell

STOCH(KDJ)(9,3,3)

10.222

Oversold

ATR(14)

0.135

High Vlolatility

CCI(14)

-155.327

Sell

Williams %R

89.215

Oversold

TRIX(12,20)

-0.942

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

2.074

Sell

MA10

2.128

Sell

MA20

2.223

Sell

MA50

2.564

Sell

MA100

2.297

Sell

MA200

1.736

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Pharmaceuticals industry's average of 6.26. The latest institutional shareholding proportion is 40.79%, representing a quarter-over-quarter increase of 20.89%. The largest institutional shareholder is James Simons, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 100.00% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Cerrone (Gabriele M)

9.28M

+7.78%

Dauntless Investment Group, LLC

1.99M

Chernett (Jorey)

2.30M

Jacob (Gary S)

45.88K

Cerity Partners LLC

12.81K

Geode Capital Management, L.L.C.

12.09K

Simon (Willy Jules)

8.95K

+0.01%

UBS Financial Services, Inc.

-100.00%

Renaissance Technologies LLC

Star Investors

13.95K

-15.48%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 4.76, which is higher than the Pharmaceuticals industry's average of 4.07. The company's beta value is -0.11. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.